To the Editor:

We performed a literature review on viral epidemics and pandemics, including the severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS), influenza H1N1, and the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the goal of identifying the neurological symptoms, signs, and complications of these infections within the context of the COVID-19 pandemic ([Figure](#fig1){ref-type="fig"}).

![Flow diagram of study selection criteria and results.](nyaa186fig1){#fig1}

Of 16 articles that included 8042 patients with H1N1, neurological involvement was reported in 1286 patients (15.99%). Excluding headaches, 771 patients had neurological involvement (9.6%) (Table [1](#tbl1){ref-type="table"}). Of 8 articles consisting of 1128 patients with MERS, 323 patients (28.6%) had neurological findings and 170 patients (15.07%) without headache. Of 5 articles with 1251 patients with SARS, 187 patients (14.95%) were reported to have neurological involvement and 6.2% (n = 78) with the exclusion of headache. Of 17 articles on 5335 patients with COVID-19, 744 patients were reported to have neurological signs, symptoms, or sequelae (13.9%) to date, with a rate of 2.47% when headache was excluded (n = 132) (Table [2](#tbl2){ref-type="table"}).

###### 

Summary of Literature Review[^a^](#tb1fn1){ref-type="table-fn"}

  Study and year                                             Number of patients   Summary of neurological findings
  ---------------------------------------------------------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  H1N1                                                                            
   Wilking et al, 2014[@bib18]                               365                  Seizure: 17, encephalitis: 4, meningitis: 4, encephalopathy: 3, meningismus: 3, focal hemorrhagic brain lesions: 2, brain infarction: 1, sensorineural hearing loss: 1
   Frobert et al, 2011[@bib19]                               181                  Seizure: 8, encephalitis: 2, encephalopathy: 1, basilar artery thrombosis: 1, myasthenic crisis: 1, decreased consciousness: 1
   Ekstrand et al, 2010[@bib20]                              303                  Seizure: 12, status epilepticus: 7, encephalopathy: 9, headache: 3, focal neurological findings: 5, myositis: 1, aphasia: 6
   Glaser et al, 2012[@bib21]                                2069                 Encephalopathy/encephalitis: 29, seizure: 44, meningitis: 3, Guillain-Barré syndrome: 1
   Jain et al, 2009[@bib22]                                  272                  Headache: 92
   Tokuhira et al, 2012[@bib23]                              81                   Seizure: 19, encephalopathy: 14, neurologic long-term complications: 5
   Dominguez-Cherit et al,2009[@bib24]                       58                   Weakness: 41, headache: 33
   Kumar et al, 2009[@bib25]                                 168                  Altered level of consciousness: 17
   Archer et al, 2009[@bib26]                                100                  Headache: 62
   Kwon et al, 2012[@bib27]                                  1389                 Seizures: 22, meningitis: 1, encephalopathy: 2
   Cao et al, 2009[@bib28]                                   426                  Headache: 83
   Libster et al, 2010[@bib29]                               251                  Headache: 6, seizures: 3
   Louie et al, 2009[@bib30]                                 1088                 Headache: 211, altered mental status: 60
   Kedia et al, 2011[@bib31]                                 307                  Seizure: 17, encephalopathy: 7
   Stein et al, 2010[@bib32]                                 478                  Headache: 51, seizure: 41, meningitis or encephalitis: 5
   Khandaker et al, 2012[@bib33]                             506                  Seizure: 38, encephalitis/encephalopathy 5, confusion/disorientation: 5, loss of consciousness: 5, paralysis/Guillain-Barré syndrome: 2.
  MERS                                                                            
   Arabi et al, 2014[@bib34]                                 12                   Headache: 2, altered consciousness: 1
   Noorwali et al, 2015[@bib35]                              261                  Headache: 59, altered consciousness: 53, focal neurological deficit: 10
   Saad et al, 2014[@bib36]                                  70                   Confusion: 18, headache: 9, seizure: 6
   Arabi et al, 2017[@bib37]                                 330                  Altered consciousness: 70, headache: 34
   Choi et al, 2016[@bib38]                                  186                  Headache: 38, altered consciousness: 10
   Assiri et al, 2013[@bib39]                                47                   Headache: 6
   Shalhoub et al, 2018[@bib40]                              32                   Altered consciousness: 2, headache: 5
   Aleanizy et al, 2017[@bib41]                              190                  No neurological symptoms or complications reported
  SARS                                                                            
   Choi et al, 2003[@bib42]                                  267                  Headache: 89, dizziness: 48, confusion: 2
   Umapathi et al, 2004[@bib5]                               206                  Large artery cerebral infarctions: 5
   Tsai et al, 2005[@bib43]                                  664                  Polyneuropathy: 3, large artery ischemic stroke: 5
   Leung and Chiu, 2004[@bib44]                              64                   Headache: 18, dizziness: 12, altered consciousness: 3
   Lien et al, 2008[@bib45]                                  50                   Headache: 2
  COVID-19                                                                        
   Mao et al, 2020[@bib46]                                   214                  Dizziness: 36, headache: 28, altered consciousness: 16, acute cerebrovascular disease: 6, ataxia: 1, seizure: 1, hypogeusia: 12, hyposmia: 11, hypopsia: 3, neuralgia: 5
   Xu et al, 2020[@bib47]                                    62                   Headache: 21
   Chen et al, 2020[@bib48]                                  274                  Headache: 3, dizziness: 21, altered consciousness: 26
   Wu et al, 2020[@bib49]                                    80                   Headache: 13
   Lian et al, 2020[@bib50]                                  788                  Headache: 75
   Wang et al, 2020[@bib51]                                  69                   Headache: 10, dizziness: 5
   Guan et al, 2020[@bib52]                                  1590                 Headache: 205, altered consciousness: 20
   Arentz et al, 2020[@bib53]                                21                   Seizure: 1
   Wan et al, 2020[@bib54]                                   135                  Headache: 24
   Chu et al, 2020[@bib55]                                   54                   Unspecified
   Huang et al, 2020[@bib56]                                 34                   Headache: 2
   Yang et al, 2020[@bib57]                                  149                  Headache: 13
   Yang et al, 2002[@bib58]                                  52                   Headache: 3
   Guan et al, 2020[@bib59]                                  1099                 Headache: 150
   Korea Centers for DiseaseControl and Prevention[@bib60]   28                   Headache: 3
   Huang et al, 2020[@bib61]                                 41                   Headache: 3
   Zheng et al, 2020[@bib62]                                 645                  Headache: 67

All studies were retrospective, except Howlett et al, 2018, which was prospective.

###### 

Neurologic Complications by Viral Disease

  Neurologic finding                                     Number of patients   Percent
  ------------------------------------------------------ -------------------- ---------
  H1N1                                                                        
   Headache                                              541                  6.73%
   Seizure                                               228                  2.84%
   Encephalitis/encephalopathy(often grouped together)   76                   0.95%
   Weakness                                              41                   0.51%
   Altered level of consciousness                        22                   0.27%
   Meningitis                                            13                   0.16%
   Speech difficulties                                   6                    0.07%
   Cognitive and memory issues                           5                    0.06%
   Cranial nerve or focal deficit                        5                    0.06%
   Neurological long-termcomplications, not specified    5                    0.06%
   Stroke                                                4                    0.05%
   Guillain-Barré syndrome                               3                    0.04%
   Hearing impairment andtinnitus                        1                    0.01%
  MERS                                                                        
   Headache                                              147                  13.03%
   Altered level of consciousness                        136                  12.06%
   Cognitive or memory issues                            18                   1.60%
   Cranial nerve or focal deficit                        10                   0.89%
   Seizure                                               6                    0.53%
  SARS                                                                        
   Headache                                              109                  8.71%
   Dizziness                                             60                   4.80%
   Stroke                                                10                   0.80%
   Altered level of consciousness                        5                    0.40%
   Neuropathy                                            3                    0.24%
  COVID-19                                                                    
   Headache                                              620                  11.74%
   Dizziness                                             62                   1.17%
   Altered level of consciousness                        62                   1.17%
   Diminished taste sensation                            12                   0.23%
   Diminished smell                                      11                   0.21%
   Stroke                                                6                    0.11%
   Neuralgia                                             5                    0.09%
   Seizure                                               2                    0.04%
   Ataxia                                                1                    0.02%

At this time, the neurological complications of COVID-19 are not fully understood, but reports of prominent neurological symptoms and complications are beginning to emerge.[@bib1] The current incidence of neurological findings with COVID-19 is relatively low, but as data from prior epidemics show, particularly prior coronavirus-related epidemics, the rate is likely to further increase. Neurological manifestations, including headache, dizziness, altered level of consciousness, focal neurological deficits, cranial nerve involvement,[@bib2] seizures, and to a lesser extent meningoencephalitis,[@bib3] more severe necrotizing encephalopathy,[@bib4] cerebral edema, and stroke,[@bib5] have been reported with the recent viral epidemics. Importantly, with prior epidemics (Table [3](#tbl3){ref-type="table"}), there are also several reports of patients developing neurological sequelae months to weeks later, including cerebellitis,[@bib6]^,^[@bib7] neuropathy,[@bib8] Guillain-Barré syndrome,[@bib9] postinfluenza myositis,[@bib10] and postviral Parkinsonism.[@bib11]

###### 

Year Identified, Total Case Numbers, and Case Fatality Rates of SARS, H1N1, MERS, and COVID-19

  Virus             Year identified   Number of countries affected   Number of cases      Number of deaths                         Case fatality rate
  ----------------- ----------------- ------------------------------ -------------------- ---------------------------------------- --------------------
  H1N1              2009              \>214                          0.7 to 1.4 billion   18 036 (confirmed) 284 000 (estimated)   0.03% (estimated)
  SARS (SARS-CoV)   2002              26                             8437                 813                                      9.6%
  MERS              2012              27                             2499                 861                                      34.5%
  COVID-19          2019              \>205                          \>2 million          33 509                                   4.8%

Coronaviruses are thought to disseminate to the central nervous system (CNS) through either hematogenous spread, retrograde neuronal dissemination, or direct invasion of the olfactory epithelium.[@bib12]

Furthermore, the ACE2 receptor, which is present in the nervous system and the skeletal system,[@bib13] was identified as the functional receptor for SARS-CoV-2.[@bib14] There is also some speculation that invasion into the CNS and damage to the medullary cardiorespiratory centers may lead to worsening respiratory symptoms.[@bib15] Also, with the prior SARS epidemic, multiple human brain specimens demonstrated direct infection of neuronal cells within the cerebral cortex and hypothalamus.[@bib16]

Additionally, there are reports of a hypercoagulable state in certain cases of COVID-19, placing patients at a higher risk of stroke, especially in the setting of acute illness and in the elderly population.[@bib17]

Given the higher prevalence of neurological sequelae reported with prior coronavirus-related pandemics, COVID-19 has the potential of leading to similar if not worse neurological sequelae due to its enhanced virulence. Neurological sequelae can lead to significant morbidity and mortality within survivors, and a heightened attention to neurological findings is required in the ensuing weeks to months.

In conclusion, with the continuing spread of COVID-19 throughout the world and from what the experience from prior epidemics has shown us, neurological findings are likely to increase; therefore, continued monitoring and early recognition is imperative.
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